Clovis Oncology (OTC: CLVS)
Some price data may be temporarily unavailable.
Clovis Oncology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Clovis Oncology Company Info
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
News & Analysis
Why Clovis Oncology Zoomed 30% Higher Today
The biotech delivers some highly encouraging news on the clinical front.
Why Clovis Oncology Stock Is Sinking Today
The biotech's Q2 financial results are concerning investors today.
Why Clovis Oncology Stock Trounced the Market Today
Investors were cheered by news of a freshly signed supply deal.
Why Clovis Oncology Stock Went Into Retreat Mode This Week
After a massive surge in its share price recently, Clovis Oncology has started to reverse course.
Why Clovis Oncology Stock Is Crushing It Today
Shareholders didn't give short-sellers what they wanted.
Why Clovis Oncology Shares Jumped 158.9% in June
The company might have vanquished delisting concerns with its surge.
Why Clovis Oncology Stock Is Taking a Step Backward Today
A key label expansion for the company's ovarian cancer drug could take longer than expected.
Why Clovis Oncology Stock Is Blasting Off Today
It reported some great initial data from one of its phase 1 clinical trials.
Valuation
Earnings Transcripts
Clovis Oncology (CLVS) Q1 2020 Earnings Call Transcript
CLVS earnings call for the period ending March 31, 2020.
Clovis Oncology (CLVS) Q4 2019 Earnings Call Transcript
CLVS earnings call for the period ending December 31, 2019.
Clovis Oncology (CLVS) Q3 2019 Earnings Call Transcript
CLVS earnings call for the period ending September 30, 2019.
Clovis Oncology (CLVS) Q2 2019 Earnings Call Transcript
CLVS earnings call for the period ending June 30, 2019.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.